Survival of Patients with Advanced Urothelial Cancer Treated with Cisplatin-Based Chemotherapy
Author Information
Author(s): SD Foss'a, C Sternberg, HI Scher, CH Theodore, B Mead, D Dearnaley, JT Roberts, E Skovlund
Primary Institution: The Norwegian Radium Hospital
Hypothesis
The study aims to assess long-term survival after cisplatin-based chemotherapy in patients with advanced urothelial transitional cell carcinoma.
Conclusion
Cisplatin-based chemotherapy can lead to long-term survival in selected patients with advanced urothelial cancer.
Supporting Evidence
- The overall cancer-related 2 year and 5 year survival rates were 21% and 11%, respectively.
- Patients with a good performance status and disease confined to lymph nodes had a 28% 5 year survival rate.
- Chemotherapy-related complications led to treatment discontinuation in 16% of patients.
Takeaway
This study shows that some patients with advanced bladder cancer can live longer if they receive a specific type of chemotherapy.
Methodology
Retrospective analysis of survival data from 398 patients treated with various cisplatin-based chemotherapy regimens across seven international oncological units.
Potential Biases
Potential selection bias due to the retrospective nature and varying treatment protocols across institutions.
Limitations
The study is retrospective and may not account for all variables affecting survival.
Participant Demographics
Patients included were primarily elderly, with 80% aged 50-79, and had measurable locally advanced or metastatic urothelial cancer.
Statistical Information
P-Value
<0.05
Confidence Interval
95% CI 13-21%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website